CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 29 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02734290
NCT02734290Phase 2Active
CompareCT.gov

A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients

Providence Health & Services·interventional·Posted Apr 12, 2016·Updated Apr 24, 2026

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab, Paclitaxel, and 1 other intervention for Triple Negative Breast Cancer. Active but no longer recruiting, targeting 29 participants across 2 sites.

Detailed Summary

The goal of this study is to establish the safety and tolerability of pembrolizumab when administered in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple Negative Breast Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2Active
201620172018201920202021202220232024202520262027
First PostedApr 12, 2016
Enrollment StartFeb 23, 2016
Primary CompletionAug 21, 2019
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.2 years ago

Interventions

Pembrolizumabdrug

Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle

Paclitaxeldrug

Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle

Capecitabinedrug

Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.